NEW YORK - With the broad S&P 500 Index gliding once again into uncharted territory and posting four straight weeks of gains, the talk of Wall Street's rally inevitably hitting a ceiling is starting to get old.
LONDON - From ketchup to hot drinks, family-run investment firms are shaking up the consumer deals market, squeezing out private equity players and forcing them to change strategy.
BEIJING/HONG KONG - China reiterated its opposition on Thursday to a European Union plan to limit airline carbon dioxide emissions and called for talks to resolve the issue a day after its major airlines refused to pay any carbon costs under the new law.
India's Piramal Healthcare to buy U.S. firm to boost R&D
MUMBAI (Reuters) - Indian drugmaker Piramal Healthcare has agreed to buy a U.S.-based healthcare data provider for $635 million to boost research and development, the company said on Wednesday, a month after it acquired the new molecules division of Germany's Bayer's.
Mumbai-based Piramal has been looking to expand its R&D portfolio after it sold its formulations business to U.S.-based Abbott Laboratories for $3.72 billion in 2010.
The company aims to close the acquisition of Decision Resources Group (DRG), based in Burlington, Massachusetts, by the end of June 30. The unit, with a team of about 300 analysts, is expected to bring in revenues of $160 million in 2012.
Piramal is trying to focus on grass-root research and high-value patents and shift away from making copycat drugs, said Siddhant Khandekar, analyst at ICICI Direct.
"The deal suggests Piramal does not want to exit the pharmaceuticals sector."
"Although the healthcare information industry size looks promising, I am not sure how Piramal can actually utilize this opportunity," he said.
The global healthcare information industry is valued about $5.7 billion and tough regulatory challenges in R&D are expected to boost demand for researched data on existing as well as new molecules, Piramal said in a statement.
DRG, which provides web-enabled information using proprietary database to global healthcare companies for their R&D projects, is growing 20 percent a year and counts 48 of the top 50 global pharmaceutical companies as clients, it said.
"Global healthcare industry is facing several challenges like rising research costs, lower drug approval rates and mounting regulatory pressures," Chairman Ajay Piramal said in a statement.
"The need for specialist information is critical and the demand is growing."
Shares in Piramal Healthcare, valued $1.37 billion, rose 1.1 percent to 434.35 rupees by 0453 GMT, in a weak Mumbai market that was down 1.55 percent.
(Reporting by Kaustubh Kulkarni; Editing by Ranjit Gangadharan)
- Tweet this
- Share this
- Digg this